$NEO SEC Filings

Filed On	Filing
05 Oct 2026	Form 4: Stone Warren, Pres & Chief Operating Officer Received 17,562 shares by exercise or conversion · Gave up 6,911 shares to cover exercise price or tax
05 Oct 2026	8-K: Results of Operations and Financial Condition; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers +1 more FORT MYERS, Fla.—NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that as part of a planned succession its Board of Dire...
03 Sep 2026	Form 4: Olivo Alicia C, EVP, GC & Business Development Gave up 2,692 shares to cover exercise price or tax
25 Aug 2026	Form 4: Stone Warren, Pres & Chief Operating Officer Received 28,106 shares by exercise or conversion · Gave up 11,060 shares to cover exercise price or tax
25 Aug 2026	S-8
14 Aug 2026	SCHEDULE 13G/A
11 Aug 2026	8-K: Departure/Election of Directors or Officers; Compensation
06 Aug 2026	Form 4: Aunan Greg D, Chief Accounting Officer Sold 20,000 shares ($321K)
04 Aug 2026	144
30 Jul 2026	144
30 Jul 2026	SCHEDULE 13G/A
30 Jul 2026	SCHEDULE 13G
28 Jul 2026	10-Q
28 Jul 2026	8-K: Results of Operations and Financial Condition
22 Jul 2026	8-K/A: Regulation FD Disclosure; Other Events On July 20, 2026, NeoGenomics, Inc. (the “Company”) issued a press release in connection with the settlement agreement described in Item 8.01 below.
20 Jul 2026	8-K: Regulation FD Disclosure; Other Events
25 Jun 2026	Form 4: Starrett Carolyn S, Director Granted 9,784 Stock Option (Right to Buy) · Granted 14,125 Restricted Stock Unit
25 Jun 2026	Form 3: Starrett Carolyn S, Director No securities owned
25 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
22 Jun 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

Comments